Retrospective Cohort Study
Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Sep 15, 2022; 14(9): 1699-1710
Published online Sep 15, 2022. doi: 10.4251/wjgo.v14.i9.1699
Table 1 Characteristics of patients according to the presence and absence of tumor deposits
Tumor deposits P value No (89624) Yes (14131) Sex 0.827 Female 43569 (48.6%) 6855 (48.5%) Male 46055 (51.4%) 7276 (51.5%) Race 0.420 White 70019 (78.1%) 11015 (77.9%) Black 10345 (11.5%) 1681 (11.9%) Others 9260 (10.3%) 1435 (10.2%) Age group, yr < 0.001a < 45 5740 (6.40%) 1231 (8.71%) 45-75 58860 (65.7%) 9387 (66.4%) ≥ 75 25024 (27.9%) 3513 (24.9%) TNM-stage < 0.001a Ι 24816 (27.7%) 111 (0.79%) ΙΙ 29374 (32.8%) 825 (5.84%) ΙΙΙ 26627 (29.7%) 7697 (54.5%) ΙV 8807 (9.83%) 5498 (38.9%) T-stage < 0.001a T1 15480 (17.3%) 181 (1.28%) T2 14312 (16.0%) 482 (3.41%) T3 47654 (53.2%) 7890 (55.8%) T4 12178 (13.6%) 5578 (39.5%) N-stage < 0.001a N0 56512 (63.1%) 1247 (8.82%) N1 22127 (24.7%) 6582 (46.6%) N2 10985 (12.3%) 6302 (44.6%) M-stage < 0.001a M0 80817 (90.2%) 8633 (61.1%) M1 8807 (9.83%) 5498 (38.9%) Liver metastasis < 0.001a No 82821 (92.4%) 10377 (73.4%) Yes 6443 (7.19%) 3627 (25.7%) Unknown 360 (0.40%) 127 (0.90%) Lung metastasis < 0.001a No 87677 (97.8%) 13053 (92.4%) Yes 1526 (1.70%) 893 (6.32%) Unknown 421 (0.47%) 185 (1.31%) Site < 0.001a Colon 71779 (80.1%) 11697 (82.8%) Rectum 16603 (18.5%) 2148 (15.2%) Unknown 1242 (1.39%) 286 (2.02%) CEA < 0.001a Normal 32166 (35.9%) 3543 (25.1%) Elevated 20936 (23.4%) 5705 (40.4%) Borderline 279 (0.31%) 48 (0.34%) Unknown 36243 (40.4%) 4835 (34.2%) Perineural invasion < 0.001a Negative 75025 (83.7%) 8437 (59.7%) Positive 7301 (8.15%) 4659 (33.0%) Unknown 7298 (8.14%) 1035 (7.32%)
Table 2 Overall survival univariate and multivariate Cox models of baseline characteristics
Univariate Cox models Multivariate Cox model Events/total HR (95%CI) P value Events/total HR (95%CI) P value Sex 0.3665 Female 19008/50424 Reference Male 20358/53331 1.01 (0.99-1.03) 0.3665 Race < 0.0001a < 0.0001a White 30958/81034 Reference 27279/73091 Reference Black 5049/12026 1.14 (1.11-1.17) < 0.0001a 4440/10821 1.19 (1.16-1.23) < 0.0001a Others 3359/10695 0.80(0.77-0.83) <.0001a 2926/9552 0.83(0.80-0.86) <.0001a Age group, yr < 0.0001a < 0.0001a < 45 1866/6971 Reference 1627/6276 Reference 45-75 20956/68247 1.17 (1.11-1.22) < 0.0001a 18394/61529 1.49 (1.42-1.57) < 0.0001a ≥ 75 16544/28537 2.78 (2.65-2.92) < 0.0001a 14624/25659 4.40 (4.17-4.63) < 0.0001a TNM-stage < 0.0001a < 0.0001a Ι 4709/24927 Reference 4154/22321 Reference ΙΙ 9334/30199 1.79 (1.73-1.85) < 0.0001a 8362/27688 0.96 (0.89-1.02) 0.2060 ΙΙΙ 13498/34324 2.46 (2.38-2.55) < 0.0001a 12086/31183 1.32 (1.21-1.43) < 0.0001a ΙV 11825/14305 9.08 (8.77-9.40) < 0.0001a 10043/12272 3.27 (2.99-3.56) < 0.0001a T-stage < 0.0001a < 0.0001a T1 2794/15661 Reference 2259/13476 Reference T2 3477/14794 1.35 (1.29-1.42) < 0.0001a 3167/13728 1.18 (1.12-1.25) < 0.0001a T3 21562/55544 2.52 (2.42-2.62) < 0.0001a 19171/50529 1.71 (1.59-1.83) < 0.0001a T4 11533/17756 5.80 (5.57-6.05) < 0.0001a 10048/15731 2.83 (2.63-3.05) < 0.0001a N-stage < 0.0001a < 0.0001a N0 16014/57759 Reference 14081/52146 Reference N1 12199/28709 1.73 (1.69-1.78) < 0.0001a 10718/25885 0.96 (0.91-1.02) 0.1880 N2 11153/17287 3.38 (3.30-3.47) < 0.0001a 9846/15433 1.44 (1.36-1.53) < 0.0001a M-stage < 0.0001a M0 27541/89450 Reference M1 11825/14305 5.05 (4.94-5.16) < 0.0001a Liver metastasis < 0.0001a < 0.0001a No 30670/93198 Reference 27418/84728 Reference Yes 8406/10070 4.67(4.56-4.79) < 0.0001a 7227/8736 1.33(1.28-1.39) < 0.0001a Lung metastasis < 0.0001a < 0.0001a No 36847/100730 Reference 32838/91390 Reference Yes 2119/2419 4.62 (4.42-4.83) < 0.0001a 1807/2074 1.32 (1.25-1.38) < 0.0001a Site < 0.0001a Colon 32774/83476 Reference Rectum 5782/18751 0.71 (0.69-0.73) < 0.0001a CEA < 0.0001a Normal 9708/35709 Reference Elevated 14098/26641 2.46 (2.40-2.53) < 0.0001a Borderline 125/327 1.51 (1.26-1.80) 0.0001a Perineural invasion < 0.0001a < 0.0001a Negative 28478/83462 Reference 27655/81868 Reference Positive 7260/11960 2.32 (2.26-2.38) < 0.0001a 6990/11596 1.22 (1.19-1.26) < 0.0001a Tumor deposits < 0.0001a < 0.0001a No 30165/89624 Reference 26523/80813 Reference Yes 9201/14131 2.73 (2.67-2.80) < 0.0001a 8122/12651 1.35 (1.31-1.38) < 0.0001a
Table 3 Sensitivity analysis for effect of tumor deposits on overall survival
Analysis HR (95%CI) P value Univariable analysis 2.73 (2.67-2.80) < 0.0001a Multivariable analysis 1.35 (1.31-1.38) < 0.0001a Propensity score analysis (with inverse probability of treatment weighting) 1.29 (1.19-1.39) < 0.0001a Multiple imputation for missing data analysis 1.39 (1.35-1.42) < 0.0001a
Table 4 Univariable Cox analysis in patients with and without tumor deposits
TDs (no) TDs (yes) RHR P value Events/total HR (95%CI) P value Events/total HR (95%CI) P value Sex 0.1265 0.0528 Female 14534/43569 Reference 4474/6855 Reference Male 15631/46055 1.02 (1.00-1.04) 0.1265 4727/7276 0.96 (0.92-1.00) 0.0528 Race < 0.0001a < 0.0001 White 23736/70019 Reference 7222/11015 Reference Black 3904/10345 1.16 (1.12-1.20) < 0.0001a 1145/1681 1.06 (1.00-1.13) 0.0536 0.91 (0.85-0.98) 0.0118a Others 2525/9260 0.79 (0.76-0.82) < 0.0001a 834/1435 0.83 (0.77-0.89) < 0.0001a 1.05 (0.97-1.14) 0.2380 Age group, yr < 0.0001a < 0.0001a < 45 1201/5740 Reference 665/1231 Reference 45-75 15238/58860 1.26 (1.19-1.34) < 0.0001a 5718/9387 1.23 (1.13-1.33) < 0.0001a 0.98 (0.88-1.08) 0.6384 ≥ 75 13726/25024 3.37 (3.18-3.58) < 0.0001a 2818/3513 2.34 (2.15-2.55) < 0.0001a 0.69 (0.63-0.77) < 0.0001a TNM-stage < 0.0001a < 0.0001a Ι 4683/24816 Reference 26/111 Reference ΙΙ 8962/29374 1.77 (1.70-1.83) < 0.0001a 372/825 2.40 (1.61-3.57) < 0.0001a 1.36 (0.91-2.02) 0.1362 ΙΙΙ 9545/26627 2.17 (2.09-2.24) < 0.0001a 3953/7697 3.05 (2.08-4.49) < 0.0001a 1.41 (0.96-2.07) 0.0836 ΙV 6975/8807 8.05 (7.76-8.36) < 0.0001a 4850/5498 9.25 (6.29-13.6) < 0.0001a 1.15 (0.78-1.69) 0.4840 T-stage < 0.0001a < 0.0001a T1 2726/15480 Reference 68/181 Reference T2 3321/14312 1.35 (1.29-1.42) < 0.0001a 156/482 0.84 (0.63-1.11) 0.2246 0.62 (0.47-0.83) 0.0012a T3 17029/47654 2.30 (2.20-2.39) < 0.0001a 4533/7890 1.84 (1.45-2.34) < 0.0001a 0.80 (0.63-1.02) 0.0602 T4 7089/12178 4.84 (4.63-5.05) < 0.0001a 4444/5578 3.69 (2.90-4.68) < 0.0001a 0.76 (0.60-0.97) 0.0286a N-stage < 0.0001a < 0.0001a N0 15350/56512 Reference 664/1247 Reference N1 8434/22127 1.53 (1.49-1.57) < 0.0001a 3765/6582 1.14 (1.05-1.24) 0.0014a 0.75 (0.68-0.81) < 0.0001a N2 6381/10985 2.86 (2.77-2.94) < 0.0001a 4772/6302 1.99 (1.83-2.16) < 0.0001a 0.70 (0.64-0.76) < 0.0001a M-stage < 0.0001a < 0.0001a M0 23190/80817 Reference 4351/8633 Reference M1 6975/8807 4.90 (4.77-5.04) < 0.0001a 4850/5498 3.13 (3.00-3.27) < 0.0001a 0.64 (0.61-0.67) < 0.0001a Site < 0.0001a < 0.0001a Colon 24983/71779 Reference 7791/11679 Reference Rectum 4595/16603 0.74 (0.71-0.76) < 0.0001a 1187/2148 0.66 (0.62-0.71) < 0.0001a 0.89 (0.83-0.96) 0.0030a CEA < 0.0001a < 0.0001a Normal 7926/32166 Reference 1782/3543 Reference Elevated 9908/20936 2.34 (2.27-2.41) < 0.0001a 4190/5705 1.95 (1.84-2.06) < 0.0001a 0.83 (0.78-0.89) < 0.0001a Borderline 95/279 1.47 (1.20-1.80) 0.0002a 30/48 1.32 (0.92-1.89) 0.1343 0.90 (0.59-1.36) 0.6100 Perineural invasion < 0.0001a < 0.0001a Negative 23417/75025 Reference 5061/8437 Reference Positive 3845/7301 2.05 (1.98-2.12) < 0.0001a 3415/4659 1.46 (1.40-1.52) < 0.0001a 0.71 (0.68-0.75) < 0.0001a Liver metastasis < 0.0001a < 0.0001a No 24811/82821 Reference 5859/10377 Reference Yes 5164/6443 4.73 (4.59-4.88) < 0.0001a 3242/3627 2.66 (2.54-2.78) < 0.0001a 0.56 (0.53-0.59) < 0.0001a Lung metastasis < 0.0001a < 0.0001a No 28622/87677 Reference 8225/13053 Reference Yes 1297/1526 4.97 (4.70-5.25) < 0.0001a 822/893 2.40 (2.23-2.58) < 0.0001a 0.48 (0.44-0.53) < 0.0001a
Table 5 N1 colorectal cancers after being restaged
Initial N stage Restaged N1 Restaged N2 Total N1a/b 18077 752 18820 N1c 1003 133 1136 Total 19080 885 19965